AVBP vs ZVRA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AVBP · ArriVent BioPharma$13.64 ▲ 11.53%
ZVRA · Zevra Therapeutics$11.59 ▲ 10.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AVBP -26.7%
- ZVRA +27.4%
Head to head
| Metric | AVBP | ZVRA |
|---|---|---|
| Price | $13.64 | $11.59 |
| Change today | ▲ 11.53% | ▲ 10.07% |
| Market cap | $672.56M | $689.66M |
| Return, 3 months | -56.0% | +1.0% |
| Return, year to date | -32.2% | +29.4% |
| Return, 1 year | -24.4% | +31.6% |
| P/E (TTM) | – | 9.5 |
| P/B | 1.8 | 2.9 |
| P/E percentile vs own 5y | 100th | 84th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +53.3% |
| Net profit growth (YoY) | -58.9% | -88.3% |
| Gross margin | – | 95.5% |
| Operating margin | – | 28.7% |
| Net margin | – | 42.8% |
| Return on equity | -53.1% | 34.8% |
| Analyst target vs. price | +130.2% | +117.9% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 35 | 60 |
| 30-day volatility | 220.3% | 67.4% |
| Max drawdown, 1 year | -64.8% | -35.5% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ZVRA is the largest of the group by market value.
- ZVRA has returned the most over the past year.
- ZVRA has been the calmest stock over the last 30 days.